Combination therapies in nonalcoholic fatty liver disease using antidiabetic and disease-specific drugs.

Differences in the primary endpoint (i.e., a ≥1-stage improvement in fibrosis without worsening of NASH) did not reach statistical significance between groups.

also in 111,027 other papers